Skip to content
IPIndiaPulseEquity intelligence
Sign inGet started
NIFTY 50
22,666.95
-144.40 (-0.63%)
NIFTY MIDCAP 100
56,942.40
-623.45 (-1.08%)
NIFTY BANK
54,665.75
-311.15 (-0.57%)
Dow Futures
52,715.50
-141.60 (-0.27%)
Indian market · As of 9:50 am IST
Results research

Concall Intelligence

Follow the Sept 2026 quarter results season by comparing what companies reported with what management said next. Search official call evidence, measurable guidance, changing outlook, operating risks, and prior commitments without treating commentary as a trading recommendation.

Open reported results
Matching calls
1
After selected filters
Transcript verified
1
Official transcript summaries on this page
Preliminary briefs
0
Presentation evidence, clearly labelled
Processing
0
Transcript filed or call source found
Tracked companies
0
Watchlist or portfolio matches

Management evidence

Generated 22 Oct, 9:52 am IST · click a summary to inspect source-linked evidence for this results quarter.

Clear filters
CompanyCall and sourcesReported resultManagement outlookEvidence-led conclusionReview
SYMBIOTEC
Symbiotec Pharmalab Limited
Pharma · Micro
Sep 2026
2 Oct 2026
Transcript verified
TranscriptPPTRecording
Result pending
No matching current-quarter result row
Optimistic outlook
No comparable prior call
Guidance maintained

Symbiotec Pharmalab reported Q1 FY27 consolidated revenue of INR 218 crores (up 7% YoY), driven mainly by the stable steroid API business. However, consolidated net profit stood lower at INR 14 crores due to a significant operational expense drag of INR 23 crores and depreciation of INR 11 crores from recently invested new businesses (biotech CDMO and complex injectables) where commercial revenues are yet to commence. Management maintains a confident revenue and EBITDA growth

Evidence summary ready
Method: Deterministic quarterly-result score from reported growth, margin direction and operating leverage. Derived only from extracted, source-linked management evidence. Pending is shown when evidence is insufficient. Measurable claims are separated from general commentary and retain outcome status when later evidence exists. Transcript-verified summaries rank above preliminary presentation briefs and source-only call evidence. Preliminary briefs are replaced automatically when an official transcript is processed. Management outlook and colours describe extracted commentary evidence; they are not buy or sell labels.